Clene Inc.
corporate_fare Company Profile
Clene Inc. (NASDAQ:CLNN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 42 items for CLNN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CLNN spans 10-Q, 424B5, 8-K, 144.
Recent high-impact activity:
- Clene 10-Q: $3.9M Q3 'Net Income' Is Non-Cash; Cash Covers Only to Mid-Q1 2027
- Clene Swings to $3.92M Third-Quarter Net Income
- Clene Files FDA NDA for ALS Drug CNM-Au8 Under Accelerated Approval Pathway
- Clene Prices $4M Registered Direct Offering at $3.28; Insiders Commit $2.1M
- Clene Prices $4M Registered Direct Offering at $3.28/Share
Financial Snapshot
Short Interest & Short Volume
5.06 days to coverFINRA reported short interest of 416,980 shares in CLNN as of the October 30, 2026 settlement, a 1.9% decrease from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 44.7% of CLNN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CLNN, detected from its recent SEC filings · based on capital-structure filings through 2026-09-16.
$4M Registered Direct Offering Priced · Insiders Commit $2.1M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →